SLC2A2 and neonatal diabetes mellitus: Sansbury et al. [74,106] first reported transient neonatal diabetes mellitus (TNDM) in four FBS patients due to homozygous SLC2A2 mutation with loss of function which resolved at a median 18 months of age, and fifth patient was still on the treatment of insulin at the age of 28 months.